SynthesisFrontiers in public health2025
Serotype distribution of invasive and non-invasive pneumococcal disease in children ≤5 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review.
Synthesis in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Serotype distribution of invasive and non-invasive pneumococcal disease in adults ≥65 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review.Frontiers in public health · 2025Pooled it
- Article
- Article
- Toward Universal Protection: A Comprehensive Review of Pneumococcal Disease, Emerging Vaccination Challenges and Future Perspectives.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Widespread implementation of pneumococcal conjugate vaccines (PCVs)-namely the 7-valent PCV (PCV7), 10-valent pneumococcal non-typeable Methods: We systematically searched the literature for observational studies (2006-2020) on pneumococcal serotype distribution in IPD, AOM, and CAP among ≤5-year-old children post-PCV introduction. Serotype-specific pooled percentage averages were calculated by post-PCV period (post-PCV7 or pooled post-PHiD-CV/PCV13), or by PCV product (PHiD-CV or PCV13) to determine the contribution of each serotype to a certain clinical manifestation. Results: Our analysis of 86 studies (47 on IPD, 30 on AOM, and 9 on CAP) shows continued reporting of several vaccine serotypes in all clinical manifestations post-PHiD-CV/PCV13, particularly serotypes 19A, 3, and 1. In PCV13 settings, serotype 19A reporting was reduced but still prevalent compared to PHiD-CV settings. Predominant non-PCV13 serotypes varied by clinical manifestation. Conclusion: Post-PCV implementation, pneumococcal epidemiology in children is intricate. The persistence of some vaccine serotypes, variations across clinical manifestations, rising antimicrobial resistance, and other factors highlight the need for new vaccine technologies providing enhanced and broader protection to children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.